Phibro Animal Health Corporation (PAHC) Q4 2026 Earnings Call Summary

1Key Financial Results and Metrics

Q4 2026 Performance::

Consolidated net sales: $396.7 million, up 5% year-over-year.

Adjusted EBITDA: $63.6 million, a 29% increase.

GAAP net income: Increased 26%, with diluted EPS rising 26%.

Adjusted net income: Increased 37%, adjusted diluted EPS up 35%.

Full Year 2026 Performance::

Consolidated net sales: $1.518 billion, up 17% from the previous year.

Adjusted EBITDA: $255 million, a 39% increase.

GAAP net income: Significant increase, driven by successful integration of the MFA business.

2Strategic Updates and Business Highlights

Sales Growth::

Legacy Animal Health business grew 8% in Q4 and 7% for the full year.

Mineral Nutrition segment saw a 20% increase in Q4 and 11% for the year.

The new MFA business contributed $354.3 million in sales, growing 70% year-over-year.

Phibro Forward Program::

The three-year transformation program concluded, with an expected cumulative EBITDA contribution of $50 million in fiscal 2027.

Facility Closure::

Planned closure of the Chicago Heights manufacturing facility to optimize the manufacturing footprint, expected to yield $15 million to $20 million in annual benefits starting in fiscal 2028.

3Forward Guidance and Outlook

Fiscal Year 2027 Guidance::

Net sales projected between $1.55 billion and $1.6 billion (2% to 5% growth).

Adjusted EBITDA forecasted at $258 million to $268 million (1% to 5% growth).

Adjusted diluted EPS expected to be between $3.41 and $3.59.

Regulatory Risks::

Minimal contribution from virginiamycin sales in Brazil is anticipated, which could impact revenue and EBITDA growth.

4Bad News, Challenges, or Points of Concern

Virginiamycin Regulatory Issues::

Sales in Brazil are expected to be minimal due to regulatory uncertainties, with $27 million in sales from the previous year not anticipated for fiscal 2027.

Decline in New MFA Business::

The new MFA portfolio experienced an 11% decline in Q4, attributed to tough comparisons with the previous year, although this was anticipated.

Increased SG&A Costs::

Higher employee-related costs impacted profitability, with SG&A expected to grow faster than revenue in fiscal 2027.

5Notable Q&A Insights

Underlying Demand Trends::

Demand for animal health products remains strong across species, with expectations for continued growth despite the virginiamycin headwind.

Business Development Focus::

The company is actively pursuing opportunities in vaccines and nutritional specialties, with a cautious approach to acquisitions.

Cash Flow and Working Capital::

Free cash flow is expected to improve in fiscal 2027, with a limited inventory build projected at $25 million to $30 million, compared to $86 million in fiscal 2026.

Impact of Mexican Border Reopening::

The phased reopening is expected to have a modest impact on U.S. beef production, with potential long-term benefits as cattle imports normalize. This summary encapsulates the essential financial metrics, strategic initiatives, outlook, and challenges faced by Phibro Animal Health Corporation as discussed in their Q4 2026 earnings call.